Protagonist Therapeutics (PTGX) Competitors $57.48 +1.44 (+2.57%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$57.48 +0.01 (+0.01%) As of 08/22/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX vs. VTRS, ASND, RDY, QGEN, MRNA, BBIO, VRNA, ELAN, BPMC, and ROIVShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Its Competitors Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories QIAGEN Moderna BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Roivant Sciences Viatris (NASDAQ:VTRS) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment. Do institutionals and insiders hold more shares of VTRS or PTGX? 79.9% of Viatris shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 0.1% of Viatris shares are held by company insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, VTRS or PTGX? Protagonist Therapeutics has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.12B0.88-$634.20M-$2.90-3.67Protagonist Therapeutics$434.43M8.23$275.19M$0.7082.11 Do analysts recommend VTRS or PTGX? Viatris presently has a consensus target price of $10.40, suggesting a potential downside of 2.35%. Protagonist Therapeutics has a consensus target price of $67.20, suggesting a potential upside of 16.91%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protagonist Therapeutics is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to VTRS or PTGX? In the previous week, Protagonist Therapeutics had 1 more articles in the media than Viatris. MarketBeat recorded 5 mentions for Protagonist Therapeutics and 4 mentions for Viatris. Protagonist Therapeutics' average media sentiment score of 1.68 beat Viatris' score of 0.00 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is VTRS or PTGX more profitable? Protagonist Therapeutics has a net margin of 24.88% compared to Viatris' net margin of -24.57%. Viatris' return on equity of 16.54% beat Protagonist Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viatris-24.57% 16.54% 7.06% Protagonist Therapeutics 24.88%8.12%7.41% Which has more risk & volatility, VTRS or PTGX? Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500. SummaryProtagonist Therapeutics beats Viatris on 15 of the 17 factors compared between the two stocks. Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.49B$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E Ratio82.1221.1431.2526.05Price / Sales8.23345.39433.91193.97Price / Cash12.4143.1937.7358.48Price / Book5.358.129.536.61Net Income$275.19M-$54.72M$3.26B$265.65M7 Day Performance2.51%2.62%2.13%2.03%1 Month Performance6.07%2.68%2.80%-0.31%1 Year Performance37.91%10.93%30.68%19.06% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics1.8064 of 5 stars$57.48+2.6%$67.20+16.9%+38.7%$3.49B$434.43M82.12120Positive NewsVTRSViatris1.6238 of 5 stars$10.63+0.2%$10.40-2.2%-9.0%$12.37B$14.74B-3.6732,000Analyst UpgradeASNDAscendis Pharma A/S3.4374 of 5 stars$194.08-2.1%$242.93+25.2%+39.4%$12.13B$490.75M-37.611,017News CoverageAnalyst ForecastRDYDr. Reddy's Laboratories3.1016 of 5 stars$14.26+0.2%$16.95+18.9%-12.1%$11.87B$3.81B21.6027,811News CoverageQGENQIAGEN3.8199 of 5 stars$48.66-1.4%$49.69+2.1%+9.4%$10.97B$1.98B28.755,765MRNAModerna4.5021 of 5 stars$28.09+0.2%$43.59+55.2%-66.5%$10.90B$3.24B-3.735,800News CoverageAnalyst ForecastBBIOBridgeBio Pharma4.6759 of 5 stars$49.02-4.5%$61.35+25.2%+97.2%$9.81B$221.90M-11.99400Insider TradeVRNAVerona Pharma PLC American Depositary Share2.4038 of 5 stars$105.79+0.5%$109.00+3.0%+290.2%$8.96B$42.28M-106.8630Short Interest ↓ELANElanco Animal Health3.0825 of 5 stars$17.72-1.4%$17.33-2.2%+22.4%$8.92B$4.44B20.609,000Analyst DowngradeBPMCBlueprint Medicines0.4734 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences3.4302 of 5 stars$11.81-0.3%$16.50+39.7%+2.1%$8.06B$29.05M-16.87860News CoverageInsider Trade Related Companies and Tools Related Companies Viatris Alternatives Ascendis Pharma A/S Alternatives Dr. Reddy's Laboratories Alternatives QIAGEN Alternatives Moderna Alternatives BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTGX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access